Cargando…
Vascular Endothelial Growth Factors and Their Inhibitors in Ocular Neovascular Disorders
The introduction of pharmacotherapy has been one of the most important advances in the management of retinal disorders. Age-related macular degeneration (AMD) was once considered as an irrepressible disease leading to permanent macular damage, however anti-vascular endothelial growth factor (anti-VE...
Autor principal: | Homayouni, Mansour |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ophthalmic Research Center
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498546/ https://www.ncbi.nlm.nih.gov/pubmed/23198057 |
Ejemplares similares
-
Myeloid-Derived Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor Are Dispensable for Ocular Neovascularization—Brief Report
por: Liyanage, Sidath E., et al.
Publicado: (2016) -
Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
por: Tan, Colin S, et al.
Publicado: (2017) -
Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization
por: Sadiq, Mohammad Ali, et al.
Publicado: (2015) -
Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization
por: Puddu, Alessandra, et al.
Publicado: (2012) -
Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
por: Al-Debasi, Tariq, et al.
Publicado: (2017)